Medseven Healthcare

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

EIN News | April 16, 2020

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

GenScript | November 10, 2020

GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...

Research

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...